Phenotypic screening Assays to seek fast cycle times from Hit, Lead to Candidate
The phenotypic screening provides relevant data to reduce the attrition rate and accelerate the translation into the clinic. At Oncodesign Services, we provide an extensive experience for cell-based assays, including phenotypic screening, to run your molecule from Hit, Lead to Candidate.
What is phenotypic screening?
Phenotypic screening is a method used in drug discovery and biological research to identify substances (molecules, peptides, RNAi…) able to alter the phenotype of a cell in a desired manner. A key difference with target-based Drug Discovery is how phenotypic screening captures the full complexity of the biological system. Rather than starting the process with a hypothesis and focusing on specific molecular targets, phenotypic screening examines the overall effects of compounds on cellular or organismal function.

Schematic representation of target based and phenotype based screening
When searching for biologically active molecules, phenotypic screening is often the most straightforward and intuitive way to discover relevant hits. The alternative is target-based screening in which a large number of compounds are screened against a single target protein, and subsequently, the active hits can be optimized further through medicinal chemistry efforts.
Phenotypic screening presents an attractive approach for the identification of novel chemical matter for therapeutic areas with complex disease mechanisms or where the disease target is unknown.

Schematic representation of phenotypic screening process
Technologies and Assays for Phenotypic Screening
Phenotype screening can be conducted using various assays to identify promising candidates, such as:
- Target identification and target expression
- Mechanism of action (MOA) studies
- In vitro screening / cell-based assays
- In vivo screening assays
Examples of technologies used for phenotypic screening:
High-throughput screening
High content imaging
Flow cytometry
Confocal microscopy
Fluorescence intensity
Fluorescence polarization,
AlphaScreen®/AlphaLISA®/AlphaPlexTM,
Luminescence (flash and glow)
Time-resolved fluorescence,
TR-FRET,
UV/vis absorbance spectra
qPCR profiling
…
Oncodesign Services offers target validation and hit selection services included phenotypic screening
Oncodesign Services is a contract research organization (CRO) specialized in drug discovery whose mission is to contribute to the discovery of innovative therapies against cancers and serious diseases with high unmet medical needs.
We offer target validation services through complementary approaches and methodologies (3D Culture, RNAi, shRNA, CrispR/Cas9, deconvolution, and other techniques) and evaluating their druggability.

Our study teams aim to increase confidence in the therapeutic target with experimented and integrated services in :
- Phenotypic screening
- Primary screening
- Hit confirmation
- Target engagement
- Cell signaling
- Generation of SAR (Structure-Activity-Relationship)
- Selectivity assessment
- Viability cell studies
- Cell engineering (CRISPR, sh-siRNA, reporter gene, molecular biology constructs, lentivirus…)
Discover EXPLORE, the best starting point for your Drug Discovery program!
Our EXPLORE offer supports companies in identifying and validating therapeutic targets by investigating preclinical proofs of concept.
The EXPLORE solution is designed to support you:
- when you are identifying potential therapeutic targets from your patient data or from other approaches in primary cell phenotyping or tumor organoid screening
- when you are experimentally validating selected targets, through complementary approaches and methodologies (RNAi, shRNA, CRISPR/Cas9, deconvolution, and other techniques) and evaluating their druggability
Case study – Phenotypic screening
1 – Discovery of target C secretion inhibitors using cell engineered phenotypic screen


2- Phenotypic screen in TNBC spheroid (3D cell line)




